Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT02177045
Other study ID # 0164-14-RMB CTIL
Secondary ID
Status Not yet recruiting
Phase N/A
First received June 26, 2014
Last updated September 30, 2014
Start date October 2014
Est. completion date October 2015

Study information

Verified date September 2014
Source Rambam Health Care Campus
Contact Diana Gainiti, Prof
Phone 972-4-7772664
Email d_gaitini@rambam.health.gov.il
Is FDA regulated No
Health authority Israel: Ministry of Health
Study type Interventional

Clinical Trial Summary

Breast lesions are a common condition, diagnosed by imaging and palpation. In order to reduce the number of biopsies performed to the definitive diagnosis of a breast lesion, an imaging method with a high degree of accuracy is needed. Ultrasound imaging with microbubbles contrast media allows the diagnosis of vascularization of the lesion, according to timing. Our hypothesis is that a highly vascularized lesion that enhances in an early timing is most likely to represent a malignant lesion and thus, deserves biopsy for a definitive diagnosis. Females over 18 years age, with a focal lesion in breast will be suitable to perform this examination.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 50
Est. completion date October 2015
Est. primary completion date October 2015
Accepts healthy volunteers No
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Female with a diagnosed breast focal lesion

Exclusion Criteria:

- Allergic conditions to contrast media,

- asthma,

- R-L shunt

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic


Related Conditions & MeSH terms

  • Malignant Neoplasm, Overlapping Lesion of Breast
  • Neoplasms

Intervention

Drug:
Sonovue, Bracco
Intravenous injection

Locations

Country Name City State
Israel Ultrasound Unit Imaging Dept Rambam Health Care Campus Haifa

Sponsors (1)

Lead Sponsor Collaborator
Rambam Health Care Campus

Country where clinical trial is conducted

Israel, 

Outcome

Type Measure Description Time frame Safety issue
Primary Tumor vascularization one year Yes